Exelixis Inc 's Revenue in the fiscal year 2025 $ 2,320.13 millions
Exelixis Inc 's Revenue in the fiscal year 2024 $ 2,168.70 millions
Exelixis Inc 's Revenue in the fiscal year 2023 $ 1,830.21 millions
Exelixis Inc 's Revenue in the fiscal year 2022 $ 1,611.06 millions
Exelixis Inc 's Revenue in the fiscal year 2021 $ 1,434.97 millions
EXEL Revenue second quarter 2026 Y/Y Growth Comment
Exelixis Inc reported Revenue increase of 10.63% year on year in the second quarter 2026, to $ 628.69 millions, this is lower than Exelixis Inc 's recent average Revenue rise of 53.44%.
Looking into second quarter 2026 results within Biotechnology & Pharmaceuticals industry 36 other companies have achieved higher Revenue growth. While Exelixis Inc ' s Revenue growth of 10.63% ranks overall at the positon no. 1669 in the second quarter 2026.
Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026
Exelixis Inc 's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
298.83 %
12.03 %
-80.37 %
(Sep 30 2011)
EXEL's II. Quarter Q/Q Revenue Comment
Exelixis Inc achieved in the II. Quarter 2026 below company average Revenue growth of 2.93% quarter on quarter, to $ 628.69 millions.
Although the II. Quarter 2026 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the II. Quarter surge, eclipses the 2.31% growth in the II. Quarter a year ago
Within Biotechnology & Pharmaceuticals industry 25 other companies have achieved higher Revenue quarter on quarter growth. While Exelixis Inc 's Revenue growth quarter on quarter, overall rank is 1359.
Exelixis Inc achieved in the II. Quarter 2026 below company average Revenue growth of 2.93% quarter on quarter, to $ 628.69 millions.
II. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 2.31% in the II. Quarter a year ago.
Within Biotechnology & Pharmaceuticals industry 25 other companies have achieved higher Revenue quarter on quarter growth. While Exelixis Inc 's Revenue growth quarter on quarter, overall rank is 1359.
Exelixis Inc 's 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Jul 03 2026)
12 Months Ending (Apr 03 2026)
12 Months Ending (Jan 02 2026)
12 Months Ending (Oct 03 2025)
12 Months Ending (Jul 04 2025)
Cumulative Revenue 12 Months Ending
$ 2,435.92
$ 2,375.49
$ 2,320.13
$ 2,288.22
$ 2,230.01
Y / Y Revenue Growth (TTM)
9.23 %
3.33 %
6.98 %
9.93 %
10.73 %
Year on Year Revenue Growth Overall
Ranking
# 2285
# 2078
# 1371
# 1248
# 590
Seqeuential Revenue Change (TTM)
2.54 %
2.39 %
1.39 %
2.61 %
-3 %
Seq. Revenue Growth (TTM) Overall
Ranking
# 2285
# 2078
# 1371
# 1248
# 590
Cumulative Revenue growth Comment
Although Exelixis Inc 's Annual Revenue growth year on year were below company's average 47.32% , Revenue announced in the Jul 03 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 9.23% year on year, from 3.33% in Apr 03 2026.
In the Healthcare sector 241 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2078 to 2285.
Although Exelixis Inc 's Annual Revenue growth year on year were below company's average 47.32% , Revenue announced in the Jul 03 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 9.23% year on year, from 3.33% in Apr 03 2026.
In the Healthcare sector 241 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2078 to 2285.
About Exelixis Inc Revenue Growth Rates (EXEL), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
13.73%